cyrilzakka/clinical-trials huggingface dataset:
Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone

The purpose of this clinical research study is to learn whether Abatacept can treat and prevent lupus flares; specifically, in patients with active lupus flares in at least one of three organ systems: skin (discoid lesions); inflammation of the lining of the heart (pericarditis), or inflammation of the lining of the lung (pleuritis/pleurisy); or inflammation of more than 4 joints (arthritis). All participants will receive prednisone or prednisone-equivalent treatment in combination with study medication. The safety of this treatment will also be studied.


Eligibility Criteria:
Inclusion Criteria:

* participants must be diagnosed with SLE and be experiencing an active lupus flare in at least one of three organ systems: skin (discoid lesions), inflammation of the lining of the heart (pericarditis), or inflammation of the lining of the lung (pleuritis/pleurisy); or inflammation of more than 4 joints within 14 days of a screening visit (arthritis)
* Stable dose of prednisone (\<30mg) for at least one month

Exclusion Criteria:

* participants experiencing an active lupus flare in the kidney or central nervous systems
* Treatment with a stable dose of azathioprine, mycophenolate mofetil, hydroxychloroquine, chloroquine, or methotrexate for less than three months prior to the study
* participants with active viral or bacterial infections
* participants with any other autoimmune disease as a main diagnosis
* Prior treatment with rituximab
Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy

Many patients undergoing flexible bronchoscopy (FB) experience anxiety and discomfort during the procedure. The investigators want to evaluate whether an additional Lorazepam premedication would improve patient satisfaction for FB.

The enrolled patients are randomized to either the control or Lorazepam groups according to a random sample chart of numbers. The patients complete questionnaires about baseline anxiety level and satisfaction for FB within 24 hours after the FB.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients (aged 18 years or older) admitted to the Respiratory Department

Exclusion Criteria:

* outpatient procedures
* therapeutic bronchoscopy
* expected operation or discharge within 24 hours after the FB
* sedative premedication
* endotracheal intubation with mechanical ventilation
* inability to speak Korean
Comparison Of The Analgesia Obtained By Infiltration For The Joinings Of Episiotomies (Liropep)

Lateral episiotomy is a current care practiced with childbirth room. One of the problems encountered with this surgical act is the residual pain on perineal scar level. Maximal during the first 24 hours, this pain can persist several days or several weeks hampering to variable degrees a normal recovery of autonomy and comfort of life. Some studies have shown the interest of ropivacaine, local anaesthetic with a long action's duration for proctologic surgeries and for the cure of inguinal hernia. A recent study shown the ropivacaine perineal infiltration used prior perineorrhaphy allows an absence of post-partum pain for 24 to 27% of cases and a first analgesics request delayed to ten hours.

Methodology: 165 parturients having an epidural analgesia and an episiotomy were enrolled. The perineal infiltration was randomized according to 3 equal groups (placebo, ropivacaine 0,75%, lidocaine 1%) and realised prior perineorrhaphy. then The parturient were followed during the 24 first hours. This study was designed as double blind and the study conduct was standardized in order to get only variable such as the episiotomy infiltration.


Eligibility Criteria:
Pre-inclusion criteria :

* Assent of participation in the study signed
* Major parturient (\> 18 years) in the course of work in room of childbirth
* Mono-foetal pregnancy
* Presentation at the top

Inclusion Criteria:

* Checking of the criteria of pre-inclusion
* Oral confirmation of the assent of the patient
* ASA 1 or 2
* Childbirth by low way
* Patient having an epidural analgesia
* Patient having an episiotomy
* Counter-indication with the ropivacaïne

Pre-exclusion criteria :

* Absence of signed assent of participation in the study
* Counter indication with the lidocaïne
* General counter-indications suitable for the epidural anaesthesia , independently of the local anaesthetic used
* Counter-indications with the infiltration: patient under anticoagulants, coagulopathy
* Allergy to the lidocaine or the ropivacaine
* Allergy to the one of analgesics per bones used in the assumption of responsibility of routine
* Severe insufficiency hepatic and/or renal and/or ulcerates gastro-duodénal (in the case of anti-inflammatory drug regulation not steroid during the postpartum)
* Minor
* Major protected within the meaning of the law Huriet
* Patient during one time of exclusion following another biomedical study

Exclusion Criteria:

* Absence of oral confirmation of the assent of the patient
* Infection or ignition of the point of puncture
* Analgesia epidural not functional
* Dural breach
* Appearance of ascribable side effects to only the anaesthetic buildings at the time of epidural analgesia
* Median Episiotomy (increased risk of lesions of the sphincter)
* Need for an instrumentation at the time of expulsion
* Haemorrhage of the delivery requiring a blood transfusion and/or general anaesthesia in urgency with surgical operation for haemostasis
Phosphodiesterase-5-inhibitors for Right Heart Failure After Left Ventricular Assist Device Implantation

Refractory right heart failure is common during the postoperative period after left ventricular assist device implantation. Oral phosphodiesterase-5 inhibitors are oft initiated in order to facilitate weaning from the intravenous inotropic substances. following this period many patients continue to receive the same medication in the long term, despite missing data on its therapeutic effect on right ventricular function.We hypothesise that beyond the acute postoperative period no additional benefit from the phosphodiesterase-5 inhibitors exists. The aim of the study is a detailed clinical and echocardiographic assessment of the right ventricular function after discontinuation of the medication in patients pretreated for at least one month after receiving left ventricular assist device.

The study aims to assess clinical and echocardiographic measures of right ventricular function before and after discontinuation of the oral phosphodiesterase-5 inhibitor in patients on left ventricular device support. At baseline and after discontinuation of the medication patients will receive a clinical examination and New York Heart Association Classification, echocardiographic assessment of right ventricular function, cardiopulmonary exercise testing, 6 minute walking test and assessment of quality of life. The primary outcome is the change of the quantitative echocardiographic parameters of right ventricular function at follow-up. Secondarily, we aim to assess the change in cardiopulmonary exercise capacity, the 6-minute walking distance and quality of life.

Eligibility Criteria:
Inclusion Criteria:

* Age \>18 y.o.
* clinically stable, ambulatory heart failure patients on left ventricular assist device support
* implantation \> 1 month before inclusion in the study
* uninterrupted therapy with an oral phosphodiesterase-5 inhibitor initiated during the early postoperativ period due to right heart failure

Exclusion Criteria:

* unable to provide written informed consent
* refusal to provide written informed consent
Validity Reliability of 3 Meter Backward Walk Test in Stroke Patients

The 3 m walk-back test is used to assess neuromuscular control, proprioception, protective reflexes, fall risk, and balance. In a study of healthy elderly adults, a 3-m walk-back test showed better diagnostic accuracy compared to the most commonly used measurement methods for falls in the past year. Reliability is extremely important, especially for research and clinical applications. In order to assess the risk of falling, measurement methods need to be reliable and change accurately over time. 3 m walk back test was found to be reliable in healthy elderly individuals. However, there are no studies investigating the validity and reliability of this test in stroke patients.

Balance; within the limits of the stability of the center of gravity can be controlled on the surface. Balance can be affected due to muscle weakness after stroke, abnormal muscle tone, loss of deep sensation and disturbances in vestibular mechanisms. Among all sensorimotor results of stroke, it is stated that the balance of postural control has the greatest effect on daily living activities and gait. Accurate assessment of balance in stroke patients is important in identifying appropriate aids for mobility, choosing an effective treatment program, determining safe and unsafe activities, and setting rehabilitation goals. The most common risk factor for falls is one of the most important risk factors for stroke. Therefore, reliable and accurate measurement of dynamic gait balance is an important issue in stroke patients.The 3 m walk-back test is used to assess neuromuscular control, proprioception, protective reflexes, fall risk, and balance. In a study of healthy elderly adults, a 3-m walk-back test showed better diagnostic accuracy compared to the most commonly used measurement methods for falls in the past year. Reliability is extremely important, especially for research and clinical applications. In order to assess the risk of falling, measurement methods need to be reliable and change accurately over time. 3 m walk back test was found to be reliable in healthy elderly individuals. However, there are no studies investigating the validity and reliability of this test in stroke patients.

Eligibility Criteria:
Inclusion Criteria:

* 40 years or older,
* Getting a diagnosis of stroke,
* Not having cooperation and communication problems
* To be able to walk 10 m independently with or without device

Exclusion Criteria:

1. Have a neurological or orthopedic problem other than stroke that will affect functionality and balance
2. Individuals with contraindications for advanced cardiovascular disease and mobilization will not be included in the study.
CD70-targeted immunoPET Imaging of Malignant Cancers

This study aims to establish and optimize the cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in malignant cancers (renal cancer (especially clear cell renal cell carcinoma), lymphoma, or nasopharyngeal carcinoma (NPC)) will be evaluated.

Histologically confirmed malignant cancers (renal cancer (especially clear cell renal cell carcinoma), lymphoma, or nasopharyngeal carcinoma (NPC)), or patients with suspected maligant cancers (renal cancer (especially clear cell renal cell carcinoma), lymphoma, or nasopharyngeal carcinoma (NPC)) indicated by conventional diagnostic imaging will be included. Patients will also be included for routine follow-up, surveillance, and treatment efficacy evaluation.

Enrolled patients will undergo whole-body immunoPET/CT scans 1-2 hours after tracer injection (0.05-0.1 mCi/kg). The uptake of imaging tracers in tumors and normal organs/tissues will be scored visually and quantitatively.

Tumor uptake will be quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy will be calculated to assess the diagnostic efficacy. The correlation between lesion uptake and CD70 expression level determined by immunohistochemistry staining will be further analyzed. The primary exploration endpoint will be the tracers' imaging feasibility and preliminary diagnostic value compared to conventional imaging approaches like 18F-FDG PET/CT.

Eligibility Criteria:
Inclusion Criteria:

* Aged 18-80 year-old and of either sex；
* Histologically confirmed diagnosis of renal cancer (especially ccRCC)/lymphoma/NPC or suspected renal cancer/lymphoma/NPC by diagnostic imaging;
* Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.

Exclusion Criteria:

* Pregnancy；
* Severe hepatic and renal insufficiency;
* Allergic to single-domain antibody radiopharmaceuticals.
MR-Evaluation of Renal Function in Anesthetized Pediatric Patients

The goal of this study is to investigate the effect of the anesthetic agents sevoflurane or propofol on the blood flow and oxygen delivery to the kidneys.

Pediatric patients who are planned to undergo an MRI scan with generalized anesthesia will be randomized to either IV anesthesia with propofol or inhalation anesthesia with sevoflurane. Both of these anesthetic methods are commonly used for anesthesia on an everyday basis.

In addition to the clinically indicated MRI, Multiparametric MRI will be performed to visualize the effect of the anesthetic agent on renal blood flow, perfusion and oxygenation.

See the study protocol

Eligibility Criteria:
Inclusion Criteria:

* Pediatric Patients (1 month -14 years of age)
* Indicated for MRI with anesthesia
* ASA (American Society of Anesthesiologists) physical status I-III

Exclusion Criteria:

* Known renal impairment or chronic kidney disease
* Severe cardiac or pulmonary disease
* Allergy to either Propofol or Sevoflurane
* Contraindications to Magnetic Resonance Imaging
* Contraindications to either Propofol or Sevoflurane
* Declined participation or declined consent from patients, parents or guardians
* Ongoing acute kidney injury
Impact of Anesthesia Technique on Post-operative Delirium After Transcatheter Aortic Valve Implantation

Aortic stenosis is a frequent valvulopathy in Europe and North America. It occurs mainly over 65 years (2-7% of the population over 65 years). Treatment of symptomatic stenosis is an indication of aortic valve replacement. For patients with high surgical risk (EuroSCORE II\> 6), TAVI (Transcatheter Aortic Valve Implantation) is recommended. This type of procedure concerns elderly patients (75-80 years on average in the literature) therefore the anesthesia technique must be optimal. The postoperative complications are, on the one hand, well-described surgical complications (Cardiogenic shock, bleeding, rhythm disorders, renal insufficiency) and, on the other hand, those related to anesthesia which are less well characterized. There is no consensus on best anesthesia technique for TAVI procedure managment. Between teams practices are different. It may consist of general anesthesia (GA) or local anesthesia with sedation (LASed). Elderly anesthesia has specific complications, including acute cerebral disturbances (delirium) usually occurring within 24 to 48 hours postoperatively and up to 7 days. It is recommended to screen delirium for patients admitted in intensive care using the CAM-ICU scale. The aim of the study is to observe the impact of the anesthesia technique (GA versus LASed) on delirium in post-operative aortic valve replacement with TAVI procedure


Eligibility Criteria:
Inclusion Criteria:

* Hospital admission for TAVI femoral way
* Age \> 18 years
* Psychiatric disease

Exclusion Criteria:

* Opposition of the operator (Interventional Cardiologist or Surgeon) to one of the two anesthesia technique
* Contraindication to local anesthesia with sedation: agitation, delirium, allergy to local anesthetics, risk of inhalation
* Opposition of the patient to use his data for research
Experiences With HDR-brachytherapy in Norway

There are 3 articles that will be written about the experience with HDR-brachytherapy (HDR-BT) in patients with high-risk prostate cancer in Norway as part of a doctorial thesis-project. The project will focus on survival, side-effects and dosimetry variables as the main points of interest.

First article will compare overall and prostate cancer specific-mortality in patients who has received HDR-BT compared to patients who has received external beam radiation therapy only (EBRT). Patients who have been treated with HDR-BT have been enrolled in an approved registry at Oslo University Hospital since 2004. The control group (EBRT only) data are from the Lancet published hallmark study SPCG-7 (Scandinavian Prostate Cancer Group). This is a case-control study.

Second article will focus on side-effects of HDR-BT compared to EBRT patients. Patients included in the registry described above have been sent (and completed with a 72% answer rate) a questionnaire of the standard Expanded Prostate Cancer Index (EPIC-26) form. This will be compared to patients who already have answered the same questionnaire in a previously published study (approved by the Norwegian Ethical Committee).

The Third article will investigate if there are any association between patients reporting severe adverse effects after HDR-BT and the patients dosimetry reports (i.e are there a larger dose to the urethra or rectum in these patients?)

Eligibility Criteria:
Inclusion Criteria:

* age, high-risk prostate cancer, general good Health, anatomical favourable condition for brachytherapy

Exclusion Criteria:

* poor Health, metastasis, T3b stage tumour, Prostate Specific Antigen (PSA) Levels \> 75, biological age \> 75 years
Repeatability and Reproducibility of Lens Zonule Length Measurement Using ArcScan Insight 100

The purpose of this study is to evaluate the intra-examiner repeatability and inter-examiner reproducibility in lens zonule length measurements using very high-frequency (VHF) digital ultrasound (ArcScan Insight 100).


Eligibility Criteria:
Inclusion Criteria:

* Subjects with no ocular disease except ametropia
* Subjects will be able to understand and willing to sign an informed consent

Exclusion Criteria:

* Previous ocular surgery
* Subjects not being able to tolerate or not willing to use pilocarpine eye drops
* Subjects has active ocular infection or inflammation
* Subjects not being able to look steadily
* Subjects not being able to open eyes wide in sterile saline even after topical anesthesia
Epidemiological Study to Describe Non Small Cell Lung Cancer Clinical Management Patterns in MENA. Lung-EPICLIN/ Gulf

The overall aim of the study is:

To provide accurate and reliable information regarding NSCLC clinical management across MENA region in order to detect unmet medical needs of this disease in terms of:

* Patient and hospital characteristics.
* Diagnostic and treatment approaches: initial and subsequent.
* Follow-up patterns in clinical management.
* Outcomes: symptoms, death, functionality, quality of life.
* Use of resources and burden on patients and health care systems.

Epidemiological study to describe NSCLC clinical management patterns in MENA

Eligibility Criteria:
Inclusion Criteria:

* Confirmed NSCLC diagnosis (e.g. bronchoscope or FNAB), all stages, men and women, attending the responsible department of treating this type of patients for the first time between November 1st, 2011 and August 30th, 2012 For PRO
* Sub-sample:

  * ability to read and write since they will be asked to participate in the PRO part of the study.
* Selection will not be based on the disease stage of each patient, in order to avoid a selection bias.

Exclusion Criteria:

* According to the study design there will not be any exclusion criteria in order to provide a high validity and to obtain the most accurate real daily practice information.
Long-term Outcome of Zonal Outer Retinopathy in Punctate Inner Choroidopathy or Multifocal Choroiditis

To report the long term prognosis in patients with punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) and associated zonal outer retinopathy (ZOR).


Eligibility Criteria:
Inclusion Criteria:

* Patients with punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) and associated zonal outer retinopathy (ZOR).
* Follow up over 4 years.

Exclusion Criteria:

* Patients with punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) without zonal outer retinopathy (ZOR).
A Study of TCD601 in de Novo Renal Transplant Recipients

The purpose of this study is to evaluate the safety and efficacy of TCD601 in combination with Belatacept when compared to standard of care immunosuppression therapy in de novo renal transplant patients.

The purpose of this study is to evaluate the safety and efficacy of TCD601 (siplizumab), an anti-CD2 monoclonal antibody, in combination with a CNI-free regimen of belatacept, MPA, and corticosteroids compared to a standard of care CNI-based regimen of tacrolimus, ATG, MPA and corticosteroids in de novo renal transplant patients.

Eligibility Criteria:
Key Inclusion Criteria:

* Able to understand the study requirements and provide written informed consent before and study assessment is performed
* Male or female patients ≥ 18 to 70 years of age
* Recipients of a de novo renal allograft from a heart-beating deceased, living ABO compatable, non-HLA identical living related donor

Key Exclusion Criteria:

* Subjects who have received a kidney allograft previously
* Recipient of a kidney from an HLA identical living related donor
* Recipient of a kidney from a donor after cardiac death
Evaluating Infrasonic Hemodynography

This comparative diagnostic accuracy study will determine the accuracy of a noninvasive wearable infrasonic sensor to detect the mechanical, electrical, and hemodynamic function of the cardiovascular system.

This comparative diagnostic accuracy study will determine the accuracy of a noninvasive wearable infrasonic sensor to detect the mechanical, electrical, and hemodynamic function of the cardiovascular system. 25 patients with cardiovascular disease will undergo a comprehensive echocardiogram, electrocardiogram, and cardiac catheterization while wearing a infrasonic earbud device. The infrasonic and hemodynamic waveforms will be analyzed using machine learning with the goal of correlating infrasound data captured by the earbud to the patient's cardiovascular hemodynamics.

Eligibility Criteria:
Inclusion Criteria:

* Normal Sinus Rhythm
* LV systolic function \>53%

Exclusion Criteria:

* 1. Known history of carotid artery disease
* 2. Moderate or greater valvular disease in Group 1
* 3. Other implantable devices (pacemaker, ICD, CardioMems, TENS unit, continuous glucose monitors, etc)
* 4. Active arrhythmia
* 5. Reduced Ejection Fraction (\< 35%) other than Group 4
* 6. Hearing loss